RecruitingNCT02869802

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

Sponsor

British Columbia Cancer Agency

Enrollment

190 participants

Start Date

Oct 6, 2016

Study Type

OBSERVATIONAL

Conditions

Pancreatic Cancer Cancer

Summary

Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses detailed genetic and molecular testing on tumor samples to better understand and classify different types of advanced pancreatic cancer (a type of pancreatic cancer that has spread to other parts of the body), with the goal of developing more personalized treatments. **You may be eligible if...** - You have been diagnosed with metastatic pancreatic ductal adenocarcinoma (pancreatic cancer that has spread) - You are 18 years of age or older - You are in reasonably good physical condition (able to carry out daily activities) - You are about to start your first round of chemotherapy treatment - Your organs (liver, kidneys, etc.) are functioning adequately **You may NOT be eligible if...** - Your cancer has not been confirmed by a tissue sample (biopsy) or imaging - You have already received chemotherapy for this cancer - You are in poor overall health or have significant organ problems This study helps researchers tailor future treatments to specific cancer subtypes. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURETumour Biopsy

If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.

OTHERSerial Collection of Plasma and Serum Samples

Participants will undergo serial collection of plasma and serum samples at baseline and every cycle of chemotherapy or every 4 weeks, whichever is longer, until end of study.